Philippines approves Covovax for emergency use
The Philippines has approved the emergency use of Novavax's Covovax vaccine for individuals aged 18 and above.
Covovax is the ninth vaccine to receive EUA in the country, with an efficacy rate of 89.7% against COVID-19.
The FDA chief confirmed that adverse effects from clinical trials were very mild and that each dose must be administered at least 21 days apart.
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
Topics in this story
Explore more stories about these topics